"Designing Growth Strategies is in our DNA"

U.S. Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitor, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI109142

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, U.S., 2022
    2. Pipeline Analysis
    3. Patent Snapshot
    4. New Product Launches
    5. Key Industry Developments - Mergers, Acquisitions and Partnerships
  5. U.S. Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-Tumor Necrosis Factor (TNF)
      2. Interleukin Antagonists
      3. Janus Kinase (JAK) Inhibitors
      4. Others
    2. Market Analysis, Insights and Forecast – By Application
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Others
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Subcutaneous
        2. Intravenous
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. AbbVie Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      2. Johnson & Johnson Services, Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      3. Bristol-Myers Squibb Company
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      4. Merck & Co., Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      5. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      6. Novartis AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      7. Eli Lilly and Company
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      8. Amgen Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      9. Biogen
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, U.S., 2022
    2. Pipeline Analysis
    3. Patent Snapshot
    4. New Product Launches
    5. Key Industry Developments - Mergers, Acquisitions and Partnerships
  5. U.S. Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-Tumor Necrosis Factor (TNF)
      2. Interleukin Antagonists
      3. Janus Kinase (JAK) Inhibitors
      4. Others
    2. Market Analysis, Insights and Forecast – By Application
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Others
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Subcutaneous
        2. Intravenous
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. AbbVie Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      2. Johnson & Johnson Services, Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      3. Bristol-Myers Squibb Company
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      4. Merck & Co., Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      5. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      6. Novartis AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      7. Eli Lilly and Company
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      8. Amgen Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      9. Biogen
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
Read Less

Figure 1: U.S. Anti-inflammatory Biologics Market Revenue Breakdown (USD Billion, %), By Drug Class, 2022 & 2030

Figure 2: U.S. Anti-inflammatory Biologics Market Value Share (%), By Drug Class, 2022 & 2030

Figure 3: U.S. Anti-inflammatory Biologics Market Value Share (%), By Application, 2022 & 2030

Figure 4: U.S. Anti-inflammatory Biologics Market Value Share (%), By Route of Administration, 2022 & 2030

Figure 5: U.S. Anti-inflammatory Biologics Market Value Share (%), By Distribution Channel, 2022 & 2030

Figure 6: U.S. Anti-inflammatory Biologics Market Share (%), By Company, 2022

Table 1: U.S. Anti-inflammatory Biologics Market Revenue (USD Billion) Forecast, By Drug Class, 2022–2030

Table 2: U.S. Anti-inflammatory Biologics Market Revenue (USD Billion) Forecast, By Application, 2022–2030

Table 3: U.S. Anti-inflammatory Biologics Market Revenue (USD Billion) Forecast, By Route of Administration, 2022–2030

Table 4: U.S. Anti-inflammatory Biologics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2022–2030

U.S. Anti-Inflammatory Biologics Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports